Pulse Biosciences (PLSE) Stock Analysis & AI Equity Report

Medical - Instruments & Supplies USD Explore free reports

Pulse Biosciences (PLSE) overview

Pulse Biosciences (PLSE) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 0.4m and operating profit of USD -76.9m; the year-end share price was 13.73 USD and market capitalisation was USD 931m. Pulse Biosciences is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Pulse Biosciences's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 80.7mFY 2025
Share price13.73 USDFY 2025 year end
RevenueUSD 0.4mFY 2025
Operating profitUSD -76.9mFY 2025
Net earningsUSD -72.8mFY 2025
Market capitalisationUSD 931mFY 2025 year end

About Pulse Biosciences

Pulse Biosciences develops medical devices using nanosecond pulsed-field ablation technology to target and remove cellular tissue. Its nPulse System delivers this energy, and its Vybrance Percutaneous Electrode System is designed for soft tissue ablation in percutaneous and intraoperative surgical procedures. The company has also developed applicators for study in other medical specialties and clinical applications.

Generate the Pulse Biosciences report

Pulse Biosciences is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Pulse Biosciences and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Pulse Biosciences

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.